Similar articles

• Erlotinib-induced scalp perifolliculitis.

  Rallis E, Petronic-Rosic V, Korfitis C. Rallis E, et al. Skinmed. 2012 Mar-Apr;10(2):70-1. Skinmed. 2012. PMID: 22545319
• Valuable lessons from treatment of non-small cell lung cancer with erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.

  Shrimali RK, Correa PD, Rizwanullah M. Shrimali RK, et al. BMJ Case Rep. 2008;2008:bcr0620080075. doi: 10.1136/bcr.06.2008.0075. Epub 2008 Nov 20. BMJ Case Rep. 2008. PMID: 21716815 Free PMC article. No abstract available.
• Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment.

  Tan AR, Steinberg SM, Parr AL, Nguyen D, Yang SX. Tan AR, et al. Ann Oncol. 2008 Jan;19(1):185-90. doi: 10.1093/annonc/mdm444. Epub 2007 Sep 17. Ann Oncol. 2008. PMID: 17878175 Clinical Trial.
• Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer.

  Byrne BJ, Garst J. Byrne BJ, et al. Curr Oncol Rep. 2005 Jul;7(4):241-7. doi: 10.1007/s11912-005-0045-6. Curr Oncol Rep. 2005. PMID: 15946581 Review.
• Targeting the epidermal growth factor receptor in non-small cell lung cancer.

  Steins MB, Reinmuth N, Bischoff H, Kindermann M, Thomas M. Steins MB, et al. Onkologie. 2010;33(12):704-9. doi: 10.1159/000322214. Epub 2010 Nov 26. Onkologie. 2010. PMID: 21124044 Review.